Literature DB >> 26622108

Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.

Brian Erly1, William D Carey2, Baljendra Kapoor3, J Mark McKinney4, Mathew Tam5, Weiping Wang4.   

Abstract

Entities:  

Year:  2015        PMID： 26622108      PMCID： PMC4640915          DOI： 10.1055/s-0035-1564794

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN： 0739-9529            Impact factor:   1.513


× No keyword cloud information.
  91 in total

Review 1.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

2.  New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection.

Authors:  Florence Wong; Jacqueline G O'Leary; K Rajender Reddy; Heather Patton; Patrick S Kamath; Michael B Fallon; Guadalupe Garcia-Tsao; Ram M Subramanian; Raza Malik; Benedict Maliakkal; Leroy R Thacker; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2013-08-30       Impact factor: 22.682

Review 3.  Current insights in intra-abdominal hypertension and abdominal compartment syndrome.

Authors:  I E de Laet; M Malbrain
Journal:  Med Intensiva       Date:  2007-03       Impact factor: 2.491

4.  Which patients benefit from hemodialysis therapy in hepatorenal syndrome?

Authors:  Oliver Witzke; Markus Baumann; Daniel Patschan; Susann Patschan; Anna Mitchell; Ulrich Treichel; Guido Gerken; Thomas Philipp; Andreas Kribben
Journal:  J Gastroenterol Hepatol       Date:  2004-12       Impact factor: 4.029

5.  Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis.

Authors:  Mohammed A Sharawey; Eglal M Shawky; Lamia H Ali; Ahmed Ali Mohammed; Hatem A Hassan; Yasser M Fouad
Journal:  Hepatol Int       Date:  2011-03-12       Impact factor: 6.047

6.  TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.

Authors:  Martin Rössle; Alexander L Gerbes
Journal:  Gut       Date:  2010-07       Impact factor: 23.059

7.  Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

Authors:  J Saló; A Ginès; J C Quer; G Fernández-Esparrach; M Guevara; P Ginès; R Bataller; R Planas; W Jiménez; V Arroyo; J Rodés
Journal:  J Hepatol       Date:  1996-12       Impact factor: 25.083

Review 8.  Hepatorenal syndrome.

Authors:  Pere Ginès; Mónica Guevara; Vicente Arroyo; Juan Rodés
Journal:  Lancet       Date:  2003-11-29       Impact factor: 79.321

Review 9.  Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Mitra K Nadim; John A Kellum; Andrew Davenport; Florence Wong; Connie Davis; Neesh Pannu; Ashita Tolwani; Rinaldo Bellomo; Yuri S Genyk
Journal:  Crit Care       Date:  2012-02-09       Impact factor: 9.097

10.  Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis.

Authors:  Vanessa Stadlbauer; Vanessa P Stadlbauer; Gavin A K Wright; Murad Banaji; Ashis Mukhopadhya; Rajeshwar P Mookerjee; Rajeshwar Mookerjee; Kevin Moore; Rajiv Jalan
Journal:  Gastroenterology       Date:  2008-01       Impact factor: 22.682
View more
  8 in total

1.  Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.

Authors:  Kannan Sridharan; Gowri Sivaramakrishnan
Journal:  J Gen Intern Med       Date:  2017-09-18       Impact factor: 5.128

Review 2.  Management of Liver Decompensation in Advanced Liver Disease (Renal Impairment, Liver Failure, Adrenal Insufficiency, Cardiopulmonary Complications).

Authors:  Luis Téllez; Antonio Guerrero
Journal:  Clin Drug Investig       Date:  2022-05-06       Impact factor: 3.580

3.  Diagnostic utility of the serum-ascites albumin gradient in Mexican patients with ascites related to portal hypertension.

Authors:  Enrique Cervantes Pérez; Gabino Cervantes Guevara; Gabino Cervantes Pérez; Guillermo Alonso Cervantes Cardona; Clotilde Fuentes Orozco; Kevin Josué Pintor Belmontes; Bertha Georgina Guzmán Ramírez; Laura Lizeth Reyes Aguirre; Francisco José Barbosa Camacho; Aldo Bernal Hernández; Alejandro González Ojeda
Journal:  JGH Open       Date:  2020-08-08

Review 4.  Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Authors:  Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

5.  A Noninvasive Imaging Toolbox Indicates Limited Therapeutic Potential of Conditionally Activated Macrophages in a Mouse Model of Multiple Organ Dysfunction.

Authors:  Jack Sharkey; Lorenzo Ressel; Nathalie Brillant; Lauren Scarfe; Bettina Wilm; B Kevin Park; Patricia Murray
Journal:  Stem Cells Int       Date:  2019-04-01       Impact factor: 5.443

6.  Hepatorenal syndrome: a Nationwide Trend Analysis from 2008 to 2018.

Authors:  Jagmeet Singh; Dushyant Singh Dahiya; Asim Kichloo; Gurdeep Singh; Katayoun Khoshbin; Hafeez Shaka
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

7.  Renal-function change after transjugular intra-hepatic portosystemic shunt placement and its relationship with survival: a single-center experience.

Authors:  Min Lang; Angela L Lang; Brian Q Tsui; Weiping Wang; Brian K Erly; Bo Shen; Baljendra Kapoor
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-12-03

Review 8.  Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges.

Authors:  Hsuan Yeh; Chung-Cheng Chiang; Tzung-Hai Yen
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.